Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

NeuroPace (NPCE) EBT Margin (2020 - 2025)

Historic EBT Margin for NeuroPace (NPCE) over the last 6 years, with Q3 2025 value amounting to 13.08%.

  • NeuroPace's EBT Margin rose 138500.0% to 13.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.68%, marking a year-over-year increase of 129200.0%. This contributed to the annual value of 34.35% for FY2024, which is 155500.0% up from last year.
  • Per NeuroPace's latest filing, its EBT Margin stood at 13.08% for Q3 2025, which was up 138500.0% from 34.72% recorded in Q2 2025.
  • NeuroPace's 5-year EBT Margin high stood at 13.08% for Q3 2025, and its period low was 123.58% during Q2 2022.
  • For the 5-year period, NeuroPace's EBT Margin averaged around 58.42%, with its median value being 50.5% (2021).
  • Per our database at Business Quant, NeuroPace's EBT Margin plummeted by -730800bps in 2022 and then skyrocketed by 675800bps in 2023.
  • NeuroPace's EBT Margin (Quarter) stood at 97.22% in 2021, then rose by 12bps to 86.01% in 2022, then soared by 58bps to 35.89% in 2023, then surged by 33bps to 24.06% in 2024, then surged by 46bps to 13.08% in 2025.
  • Its EBT Margin stands at 13.08% for Q3 2025, versus 34.72% for Q2 2025 and 28.89% for Q1 2025.